STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced the successful completion of a USD $30 million Series B financing round.
Who to call at STORM Therapeutics, and when
A new round usually means STORM Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day STORM Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at STORM Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
STORM Therapeutics
Location
Cambridge, England, United Kingdom
About
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.
STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment STORM Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeutics